Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib.
10.3779/j.issn.1009-3419.2025.106.12
- Author:
Jia YU
1
;
Shengxiang REN
1
Author Information
1. Department of Oncology, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200082, China.
- Publication Type:English Abstract
- Keywords:
Anaplastic lymphoma kinase-tyrosine kinase inhibitors;
Brigatinib;
Efficacy;
Lung neoplasms;
Non-small cell lung cancer;
Safety
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/enzymology*;
Lung Neoplasms/enzymology*;
Pyrimidines/therapeutic use*;
Organophosphorus Compounds/therapeutic use*;
Antineoplastic Agents/therapeutic use*;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2025;28(6):450-459
- CountryChina
- Language:Chinese
-
Abstract:
The discovery of anaplastic lymphoma kinase (ALK) tyrosine kinase gene rearrangement mutations in non-small cell lung cancer (NSCLC) has driven continuous advancements in ALK-targeted therapies. The next generation of ALK tyrosine kinase inhibitor, Brigatinib, has demonstrated significant efficacy in patients with ALK-positive NSCLC, offering clinical benefits in deep response of tumor, treatment of brain metastases patients, quality of life, and long-term survival. This review will provide current advancements and exploratory directions for Brigatinib.
.
